-
Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
COVID-19 UPDATESNovavax has demonstrated its ability to quickly develop viable vaccine candidates for emerging infectious diseases such as COVID-19.
-
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious diseases globally through the discovery and development of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
-
Insights
Insights
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.
MEDICAL PROFESSIONAL HUB
Novavax is a biotechnology company committed to help address serious infectious diseases globally through the discovery, development, and delivery of innovative vaccines to patients around the world.
Resources prepared for you to answer your questions
Global authorization site of Novavax COVID-19 Vaccine (recombinant, adjuvanted)
Product summary for healthcare professionals, patient information, expiry date checker, FAQs, and more
Global medical information site
Ask medical questions, report adverse events, and report product quality complaints
Publications, posters & presentations
Source in-depth information including clinical trial protocols of our research areas
PREVENT-19 fact sheet
Review the summary of PREVENT-19, a phase 3, randomized, observer-blinded, placebo-controlled trial evaluation of NVX-CoV2373 vaccine efficacy, immunogenicity, and safety in adults 18 and older.

Investigator-Initiated Studies (IIS)
The Novavax IIS program supports clinical and non-clinical research that addresses important unmet scientific or medical needs aligned with Novavax's areas of interest. Support for an approved IIS may include funding, Novavax product, or both.

Become a clinical trial site with Novavax
If you are interested in participating as a clinical trial site with Novavax, please complete the site questionnaire.

Science & technology
Novavax COVID-19 Vaccine is now conditionally authorized in several regions.


Science & technology
Recombinant nanoparticle vaccine technology
Science & technology
Matrix-M™ adjuvant technology
Science & technology
Our pipeline—creating tomorrow's vaccine today
Want to learn more about our vaccines?
